How Much Does Ozempic Cost in 2026?
Ozempic monthly cost by payment channel
| Channel | Monthly cost |
|---|---|
| Insurance + Ozempic Savings Card (T2D patient) | $0 to $25 |
| Insurance copay only (no Savings Card) | $25 to $100 |
| Branded telehealth (Hims/Ro/LifeMD) | $399 |
| Compounded semaglutide (when available) | $199 |
| NovoCare self-pay (Ozempic) | N/A |
| Cash retail (full WAC) | $998 |
Quick decision tree: which Ozempic path is yours?
- Do you have a type 2 diabetes diagnosis? If yes, your insurance likely covers Ozempic with prior auth. Apply for the Ozempic Savings Card → $25/fill or sometimes $0.
- Do you have insurance but no T2D diagnosis? Ozempic denial is almost certain (off-label). Switch your prescriber to write for Wegovy (same drug, weight-loss indication). Better insurance odds AND cheaper cash-pay options.
- No insurance at all? Branded telehealth at $399/month is fastest. Or pivot to Wegovy for NovoCare self-pay at $349/month or the Novo subscription program at $249/month on a 12-month plan.
- Medicare/Medicaid + T2D diagnosis? Ozempic is covered for diabetes. Savings Card does NOT work for government insurance. Standard formulary copays apply.
Ozempic coverage by major insurer
Coverage stance and per-carrier details for Ozempic. Each link goes to the full prior-auth requirements, cost table, and appeal playbook for that carrier.
Frequently asked questions
How much does Ozempic cost per month in 2026?
Range: $25 to $998 per month depending on how you pay. With commercial insurance + Ozempic Savings Card and a type 2 diabetes diagnosis: $0 to $25/month copay. Without insurance, branded telehealth runs $399/month and compounded semaglutide (when available) runs $199/month. Cash retail at full list price is $998/month, which almost no one pays. Novo Nordisk does not offer a NovoCare self-pay program for Ozempic the way they do for Wegovy; if you don't have a diabetes diagnosis, switching to Wegovy (same molecule, weight-loss-indicated) usually unlocks the NovoCare $349/month path or the $249/month subscription program.
Why is Ozempic so much harder to get covered for weight loss than Wegovy?
Ozempic is FDA-approved for type 2 diabetes only. Wegovy is the same molecule (semaglutide) FDA-approved for chronic weight management. If you have a documented type 2 diabetes diagnosis, Ozempic coverage is straightforward and Wegovy coverage is harder. If you do NOT have type 2 diabetes, the reverse is true. Insurers strictly enforce the FDA indication. Trying to get Ozempic covered for off-label weight loss almost always results in a prior-authorization denial; trying to get Wegovy for type 2 diabetes typically requires step therapy through Ozempic first.
How does the Ozempic Savings Card work?
The Ozempic Savings Card from Novo Nordisk drops your commercial-insurance copay to as little as $25 per fill (or $0 in some configurations) if your plan covers Ozempic. Novo Nordisk covers up to $150 per month of your insurer copay for up to 24 months. Government insurance (Medicare, Medicaid, Tricare, VA, DOD) is excluded by federal anti-kickback statute. You apply at novocare.com/ozempic.
Why does Wegovy cost more than Ozempic at list price when they are the same drug?
Both contain semaglutide as the active ingredient. Wegovy lists at $1,349/month vs Ozempic at $998/month. The price gap reflects different FDA indications and different commercial markets: Wegovy is dosed higher (up to 2.4 mg vs Ozempic 2.0 mg max), and Novo Nordisk priced Wegovy as a premium weight-loss product targeting cash-pay patients. Wegovy also has a NovoCare self-pay path ($349/month) and a Novo subscription program ($249-$329/month) that Ozempic does not.
What is compounded semaglutide and is it still legal in 2026?
Compounded semaglutide is a non-FDA-approved version manufactured by 503A or 503B compounding pharmacies, typically prescribed via telehealth platforms like Hims and Ro. Historically priced around $199/month, much cheaper than branded. Legal status narrowed sharply in 2025-2026: FDA ended enforcement discretion for 503B (March 2025) and 503A (February 2025) after the official semaglutide shortage was declared resolved. On April 30, 2026, the FDA proposed adding semaglutide to the 503B Bulks List exclusion. 503A retains a narrow individual-patient exception for documented allergy or specific clinical justification; cost savings alone does not qualify. Hims and Ro have largely shifted to branded drugs as a result.
Should I get Ozempic or Wegovy for weight loss?
If you have type 2 diabetes, get Ozempic - your insurance will cover it readily and the Savings Card gets you to $25/fill. If you do NOT have type 2 diabetes, get Wegovy - it's FDA-indicated for weight loss, has a higher max dose (better outcomes), and has cash-pay options Ozempic lacks. Trying to use Ozempic off-label for weight loss without a diabetes diagnosis is usually denied by insurance and forces you to pay branded telehealth prices ($399/month) when Wegovy via NovoCare ($349/month) or the subscription program ($249/month) would be cheaper.
Does Medicare or Medicaid cover Ozempic?
Medicare Part D covers Ozempic for type 2 diabetes (it does NOT cover GLP-1s prescribed for weight loss alone, which is the federal Medicare statutory exclusion). Medicaid varies by state but most state Medicaid programs cover Ozempic for T2D. Neither covers Ozempic for off-label weight loss. The Ozempic Savings Card does NOT work for Medicare/Medicaid patients regardless of indication, due to federal anti-kickback law. If you are on Medicare and need a GLP-1, the realistic paths are: documented T2D + Ozempic, or cash-pay Wegovy/Zepbound.
How much weight loss does Ozempic produce vs Wegovy?
Ozempic produces about 11.6% mean weight loss at peak (STEP-2 trial in T2D patients, off-label dose). Wegovy produces about 14.9% (STEP-1 trial in non-diabetic patients). The gap is partly the higher Wegovy dose (2.4 mg vs Ozempic 2.0 mg) and partly the patient population (T2D patients tend to lose less weight on GLP-1s than non-diabetic patients). For pure weight-loss outcomes, Wegovy is the better choice; for combined glycemic control + modest weight loss, Ozempic is fine.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.